For a 46‑year‑old man with type 3c diabetes, weight 88 kg, impaired renal function (creatinine 1.18 mg/dL, eGFR ≈ 77 mL/min) who is on Lantus (insulin glargine) 10 U daily, insulin‑to‑carbohydrate ratio 10 g per unit, and insulin‑sensitivity factor 50 mg/dL per unit, is it appropriate to increase basal Lantus to 15 U, adjust the insulin‑sensitivity factor to 25 mg/dL per unit, and set the insulin‑to‑carbohydrate ratio to 1 U per 8 g carbohydrate?

Insulin Adjustment Plan Assessment

Your proposed adjustments are reasonable and align with standard titration protocols, but proceed cautiously given the impaired renal function and type 3c diabetes context.

Basal Insulin Increase (10 U → 15 U Lantus)

The increase from 10 to 15 units of Lantus is appropriate and follows evidence-based titration guidelines. The 2025 ADA Standards recommend starting basal insulin at 10 units daily (or 0.1-0.2 units/kg) and increasing by 2 units every 3 days to reach fasting plasma glucose goals without hypoglycemia 1. Your 5-unit increase is within this framework, though slightly more aggressive than the incremental approach.

Key considerations for your situation:

• Renal function impact: With eGFR ~77 mL/min (Stage 2 CKD), you're in a zone where insulin glargine requirements may actually be higher than in normal renal function. Research shows that glargine dose requirements don't decrease significantly until eGFR drops below 60 mL/min 2, 3. At eGFR <60, glargine requirements drop by approximately 27-30% compared to normal function 2.

• Type 3c diabetes specificity: Pancreatogenic diabetes is characterized by hepatic insulin resistance due to both insulin and pancreatic polypeptide deficiency 4. This may necessitate higher insulin doses than typical type 2 diabetes.

• Monitoring imperative: The FDA label explicitly states that dose adjustments must occur under medical supervision with appropriate glucose monitoring 5. Test fasting glucose daily during titration.

Insulin Sensitivity Factor (50 → 25 mg/dL per unit)

This change doubles your correction insulin potency and requires careful consideration. Moving from ISF 50 to ISF 25 means each unit of correction insulin will lower blood glucose by 50 mg/dL instead of 25 mg/dL—this is a substantial increase in insulin sensitivity assumption.

Critical safety points:

• This aggressive adjustment significantly increases hypoglycemia risk, particularly given your renal impairment. Even at eGFR 77, there is some reduction in insulin clearance that becomes more pronounced over time 2.

• Start conservatively: Consider an intermediate step (ISF 35-40) before moving to 25, especially since you're simultaneously increasing basal insulin.

• The combination of increased basal insulin AND more aggressive correction dosing compounds hypoglycemia risk.

Insulin-to-Carbohydrate Ratio (1:10 → 1:8)

This 20% increase in mealtime insulin is reasonable but monitor closely. Moving from 1 unit per 10g carbs to 1 unit per 8g carbs increases your prandial insulin by 25%.

Implementation strategy:

• Apply this change to one meal at a time (typically the largest meal or the one with greatest postprandial excursions) rather than all meals simultaneously 1.

• Monitor 2-hour postprandial glucose to assess adequacy.

• For type 3c diabetes, ensure adequate pancreatic enzyme replacement therapy is in place, as exocrine insufficiency affects carbohydrate absorption and can cause unpredictable glucose responses 4.

Renal Function Monitoring

Your creatinine of 1.18 mg/dL with eGFR ~77 mL/min places you at a critical threshold. Research demonstrates that:

• Insulin glargine requirements remain relatively stable until eGFR drops below 60 mL/min 2, 3.
• If your renal function declines further, you may need to reduce insulin doses by up to 30% 2.
• Long-acting insulin analogues like glargine can accumulate during acute worsening of renal function, causing prolonged hypoglycemia 6.

Monitor creatinine/eGFR regularly (every 3-6 months minimum) and be prepared to reduce insulin doses if renal function declines.

Hypoglycemia Prevention Protocol

Given the aggressive nature of these combined adjustments:

• Prescribe glucagon for emergency hypoglycemia as recommended by guidelines 1.
• Test fasting glucose daily and pre-meal glucose before each meal during the adjustment period.
• If hypoglycemia occurs without clear cause, reduce the corresponding insulin dose by 10-20% 1, 5.
• Be particularly vigilant for nocturnal hypoglycemia with the increased basal dose.

Type 3c-Specific Considerations

For pancreatogenic diabetes, metformin should ideally be first-line therapy when possible, as it reduces pancreatic cancer risk (a major concern in type 3c diabetes, particularly with chronic pancreatitis) 4. However, with your renal function, metformin use requires careful consideration of the eGFR threshold (typically contraindicated <30 mL/min, use cautiously 30-45 mL/min).

Ensure pancreatic enzyme replacement therapy is optimized to prevent malabsorption-related glucose variability and nutritional deficiencies 4.

Bottom Line Algorithm

1. Increase Lantus to 15 units at the same time daily 1, 5
2. Adjust ICR to 1:8 for the largest meal first, then extend to other meals if successful
3. Use ISF 35-40 initially rather than jumping to 25; reassess after 1-2 weeks
4. Test glucose: fasting daily, pre-meal, and 2-hour post-meal during titration
5. Reduce any insulin component by 10-20% if unexplained hypoglycemia occurs 1
6. Recheck renal function in 3 months; if eGFR drops below 60, anticipate need for 25-30% insulin dose reduction 2
7. Rotate injection sites within the same region to prevent lipodystrophy 5